- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07837674
Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine
The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension.
Isobaric chloroprocaine is a local anesthetic increasingly used for spinal anesthesia to reduce the duration of sensory and motor blocks compared to bupivacaine, allowing for faster postoperative recovery. However, certain medications used during surgery may possibly influence the duration of spinal anesthesia. Among these is dexamethasone, a drug belonging to the corticosteroid family. Dexamethasone is a well-known and commonly used medication in anesthesia to prevent postoperative nausea and vomiting. It is also used by anesthesiologists to reduce pain in the context of fast functional recovery after surgery. The safety of single-dose intravenous dexamethasone is therefore established in the context of anesthesia for several types of surgery.
Medical literature demonstrates that dexamethasone can prolong the effect of certain local anesthetics when administered intravenously or perineurally (near the nerves), and sometimes has no effect on the duration of local anesthetics administered for spinal anesthesia. Currently, no information is available in the literature on the effect of intravenous dexamethasone on the duration of a spinal anesthesia with isobaric chloroprocaine.
This study aims to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Julie Desroches, PhD
- Numéro de téléphone: 24542 514-890-8000
- E-mail: anesthesie.recherche.chum@ssss.gouv.qc.ca
Sauvegarde des contacts de l'étude
- Nom: Stephan Williams, MD, PhD
- Numéro de téléphone: 12132 514-890-8000
- E-mail: stephan.williams@umontreal.ca
Lieux d'étude
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3E4
- Santé Québec - Centre hospitalier de l'Université de Montréal
-
Contact:
- Julie Desroches, PhD
- Numéro de téléphone: 24542 514-890-8000
- E-mail: anesthesie.recherche.chum@ssss.gouv.qc.ca
-
Contact:
- Stephan Williams, MD, PhD
- Numéro de téléphone: 12132 514-890-8000
- E-mail: stephan.williams@umontreal.ca
-
Chercheur principal:
- Stephan Williams, MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age between 18 and 90 years old
- ASA status I to III inclusively
- Planned lower body surgery under spinal anesthesia with chloroprocaine
- Signed informed consent form
Exclusion Criteria:
- Contraindication to spinal anesthesia: infection at the puncture site, congenital or acquired coagulopathy
- Preexisting neuropathy or nerve block that could interfere with study assessments
- Allergy or hypersensitivity to local anesthetics, dexamethasone, or other medications used in the study
- Preoperative use of corticosteroids
- Patient refusal
- Inability to consent
- Language barrier, psychiatric, physical, or mental condition making sensory and motor blocks assessment impossible despite prior instruction
- Administration of any intrathecal adjuvant (fentanyl, morphine, clonidine, dexmedetomidine, epinephrine, or others) along with chloroprocaine
- Perioperative intravenous dexmedetomidine administration
- Conversion to general anesthesia
- Impossible post-anesthesia care unit assessment: patient still intubated / transfer to intensive care unit, research team constraints, or other reasons
- Assessment in the recovery room impossible: medical condition (shock, delirium, major agitation, altered state of consciousness, or other), transfer to the intensive care unit, research team constraints, or other
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Intravenous dexamethasone
During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered intravenously over one minute. The study drug will be prepared by an independent assistant. |
Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia with chloprocaine
Autres noms:
|
|
Comparateur placebo: Intravenous normal saline
During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of 2 ml of Normal Saline will be initiated. The normal saline will be administered intravenously over one minute. The study drug will be prepared by an independent assistant. |
Administration of a single-dose of Normal saline during spinal anesthesia with chloprocaine
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Regression of sensory block by 2 dermatomes
Délai: At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery
|
Loss of pinprick sensation by Von Frey filaments from the injection of chloroprocaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level |
At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Duration of motor block
Délai: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
Using the Bromage scale from the time of injection of chloroprocaine for spinal anesthesia until complete recovery of motor block |
At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
|
Time until the first observable regression of the motor block
Délai: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
Time between the local anesthesic injection and the first measurable regression of the motor block measured using the Bromage scale. |
At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
|
Onset of sensory block
Délai: Up to 30 minutes following spinal anesthesia
|
Time from injection of chloroprocaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation |
Up to 30 minutes following spinal anesthesia
|
|
Onset of motor block
Délai: Up to 30 minutes following spinal anesthesia
|
Time from injection of chloroprocaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale |
Up to 30 minutes following spinal anesthesia
|
|
Quality of motor block
Délai: Up to 30 minutes following spinal anesthesia
|
Maximal Bromage score The Bromage scale is a standardized tool used in neuraxial anesthesia to quantify motor block intensity in the lower extremities. It assesses a patient's ability to move their legs and feet. A scale of 0 to 3 is used: 0 - Full movement, 1- Partial block, 2 - Nearly complete block and 3 - Complete block. The maximal Bromage score reflects the deepest level of lower-limb motor block, with higher scores indicating stronger motor impairment and therefore a denser motor block. |
Up to 30 minutes following spinal anesthesia
|
|
Opioid consumption
Délai: At recovery room discharge, approximately one hour after the end of surgery
|
Total dose of opioids |
At recovery room discharge, approximately one hour after the end of surgery
|
|
Antiemetic consumption
Délai: At recovery room discharge, approximately one hour after the end of surgery
|
Total dose of antiemetics |
At recovery room discharge, approximately one hour after the end of surgery
|
|
Incidence of hypotension
Délai: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Systolic blood pressure lower than 90 mm Hg |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of bradycardia
Délai: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Heart rate slower than 50 beats per minute |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of nausea
Délai: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of nausea reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of vomiting
Délai: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of retching or vomiting reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of itching
Délai: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of itching reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of urinary retention
Délai: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of urinary retention reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of shivering
Délai: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of shivering reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of headache
Délai: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of headache reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Quality of postoperative recovery
Délai: At 24 hours after the surgery
|
QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score), giving a lowest possible score of 0 (worst outcome), and a highest possible score of 150 (optimal outcome). |
At 24 hours after the surgery
|
|
Intensity of nausea/vomiting
Délai: At 24 hours after surgery
|
Pre-established analysis of nausea/vomiting intensity at 24 hours based on the QoR-15 question. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Pain intensity
Délai: At 24 hours after surgery
|
Pre-established analysis of pain intensity at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Quality of sleep
Délai: At 24 hours after surgery
|
Pre-established analysis of sleep quality at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Surgeon's satisfaction towards spinal anesthesia
Délai: At the end of surgery, on the day of randomization
|
Unsatisfied or satisfied |
At the end of surgery, on the day of randomization
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Stephan Williams, MD, PhD, Santé Québec - CHUM
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Composés de soufre
- Produits chimiques organiques
- Préparations pharmaceutiques
- Hydrocarbures
- Hydrocarbures, cyclique
- Hydrocarbures, aromatique
- Dérivés de benzène
- Solutions cristalloïdes
- Solutions isotoniques
- Solutions
- Acides sulfoniques
- Acides de soufre
- Benzènesulfonates
- Arylsulfonates
- Acides arylsulfoniques
- Dobésilate de calcium
- Solution saline
Autres numéros d'identification d'étude
- 2027-13916
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .